Triazolopyridazine LRRK2 kinase inhibitors

被引：24

作者：

Franzini, Maurizio ^{[1
]}

Ye, Xiaocong M. ^{[1
]}

Adler, Marc ^{[2
]}

Aubele, Danielle L. ^{[1
]}

Garofalo, Albert W. ^{[1
]}

Gauby, Shawn ^{[3
]}

Goldbach, Erich ^{[3
]}

Probst, Gary D. ^{[1
]}

Quinn, Kevin P. ^{[3
]}

Santiago, Pam ^{[3
]}

Sham, Hing L. ^{[1
]}

Tam, Danny ^{[4
]}

Anh Truong ^{[1
]}

Ren, Zhao ^{[4
]}

机构：

[1] Elan Pharmaceut, Dept Med Chem, San Francisco, CA 94080 USA

[2] Elan Pharmaceut, Dept Mol Design, San Francisco, CA 94080 USA

[3] Elan Pharmaceut, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA

[4] Elan Pharmaceut, Dept Assay Dev, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 07期

关键词：

LRRK2; Parkinson's; Inhibition; Kinase; Treatment; Discovery; Wild-type; G2019S mutant; Phosphorylation; SAR; Activity; Selectivity; Bioisostere; Hinge; HTS; Oxidative metabolism; Binding mode; Synthesis; CENTER-DOT-LICL; PARKINSONS-DISEASE; HETEROAROMATICS; AROMATICS; ZINCATION; TARGETS; BINDING;

D O I：

10.1016/j.bmcl.2013.02.043

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [1,2,4]triazolo[4,3-b]pyridazines that are potent against both wild-type and mutant LRRK2 kinase activity in biochemical assays and show an unprecedented selectivity towards the G2019S mutant. A structural rational for the observed selectivity is proposed. (C) 2013 Elsevier Ltd. All rights reserved.

引用

下载

页码：1967 / 1973

页数：7

共 50 条

[21] Assaying the Kinase Activity of LRRK2 in vitro
Lewis, Patrick A.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2012, (59):
[22] Effects of LRRK2 Inhibitors in Nonhuman Primates
Miller, Glen K.
Kuruvilla, Sabu
Jacob, Binod
LaFranco-Scheuch, Lisa
Bakthavatchalu, Vasudevan
Flor, Jason
Flor, Kristin
Ziegler, Julie
Reichard, Christine
Manfre, Phil
Firner, Suzanne
McNutt, Tara
Quay, Diane
Bellum, Sairam
Doto, Greg
Ciaccio, Paul J.
Pearson, Kara
Valentine, Jack
Fuller, Pete
Fell, Matt
Tsuchiya, Takayuki
Williamson, Toni
Wollenberg, Gordon
TOXICOLOGIC PATHOLOGY, 2023, 51 (05) : 232 - 245
[23] Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment
Klein, Christian L.
Rovelli, Giorgio
Springer, Wolfdieter
Schall, Christoph
Gasser, Thomas
Kahle, Philipp J.
JOURNAL OF NEUROCHEMISTRY, 2009, 111 (03) : 703 - 715
[24] Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
Nichols, R. Jeremy
Dzamko, Nicolas
Hutti, Jessica E.
Cantley, Lewis C.
Deak, Maria
Moran, Jennifer
Bamborough, Paul
Reith, Alastair D.
Alessi, Dario R.
BIOCHEMICAL JOURNAL, 2009, 424 : 47 - 60
[25] Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models
Kramer, Thomas
Lo Monte, Fabio
Goering, Stefan
Amombo, Ghislaine Marlyse Okala
Schmidt, Boris
ACS CHEMICAL NEUROSCIENCE, 2012, 3 (03): : 151 - 160
[26] Inhibitors of LRRK2 Kinase Activity To Probe the Treatment Option in Parkinson's Disease
Rautio, Jarkko
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 9414 - 9415
[27] Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
C. P. Gonzalez-Hunt
E. A. Thacker
C. M. Toste
S. Boularand
S. Deprets
L. Dubois
L. H. Sanders
Scientific Reports, 10
[28] LRRK2
Farrer, M.
MOVEMENT DISORDERS, 2010, 25 : S579 - S579
[29] Mutant LRRK2 Toxicity in Neurons Depends on LRRK2 Levels and Synuclein But Not Kinase Activity or Inclusion Bodies
Skibinski, Gaia
Nakamura, Ken
Cookson, Mark R.
Finkbeiner, Steven
JOURNAL OF NEUROSCIENCE, 2014, 34 (02): : 418 - 433
[30] Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease
Gonzalez-Hunt, C. P.
Thacker, E. A.
Toste, C. M.
Boularand, S.
Deprets, S.
Dubois, L.
Sanders, L. H.
SCIENTIFIC REPORTS, 2020, 10 (01)

← 1 2 3 4 5 →